Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046

JOHNSON & JOHNSON

 (JNJ)

91
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisionsForum 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

08/21/2012| 06:13pm US/Eastern
Recommend:
0
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Recommend :
0
Partner Area
React to this article
 
Latest news on JOHNSON & JOHNSON
11h ago EU fines Lundbeck and others 146 mln euros for blocking rival drugs
12h ago EU fines Lundbeck and others 146 million euros for blocking rival drugs
15h ago EU fines Lundbeck, 8 others 146 million euros for blocking cheaper drugs
1d ago Call for overhaul of drug industry business model
2d ago JOHNSON & JOHNSON: J&J, in new $1 billion deal, bolsters prostate-cancer role
2d agoDJJOHNSON & JOHNSON: J&J to Acquire Privately Held Aragon Pharma
2d agoDJJOHNSON & JOHNSON: J&J to Acquire Privately Held Aragon Pharma for Up to $1 Bil..
2d ago JOHNSON & JOHNSON: to buy Aragon for up to $1 billion
2d ago JOHNSON & JOHNSON: Updated Results of Two Phase 2 ibrutinib Studies in Patients..
2d ago JOHNSON & JOHNSON: Announces Definitive Agreement To Acquire Aragon Pharmaceuti..
Advertisement
Chart
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
Johnson _ Johnson : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.